[1] ANKLEY G T,BENNETT R S,ERICKSON R J,et al.Adverse outcome pathways:a conceptual framework to support ecotoxicology research and risk assessment [J].Environ Toxicol Chem,2010,29:730-741. [2] GROH K J,CARVALHO R N,CHIPMAN J K,et al.Development and application of the adverse outcome pathway framework for understanding and predicting chronic toxicity:I.Challenges and research needs in ecotoxicology [J].Chemosphere,2015,120:764-777. [3] VILLENEUVE D L,CRUMP D,GARCIA-REYERO N,et al.Adverse outcome pathway (AOP) development I:strategies and principles [J].Toxicol Sci,2014,142(2):312-320. [4] SONICH-MULLIN C,FIELDER R,WILTSE J,et al.International programme on chemical safety:IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis [J].Regul Toxicol Pharmacol,2001,34:146-152. [5] National Research Council (NRC).Toxicity testing in the twenty-first century:A vision and a strategy [R].Washington D C:National Academy of Sciences,2007. [6] OECD.Guidance document on developing and assessing adverse outcome pathways.In Series on Testing and Assessment,No.184,Vol.ENV/JM/MONO(2013)6,p.45 [S].France:Organisation for Economic Cooperation and Devleopment,Environment Directorate Paris,2013. [7] EDWARDS S W,TAN Y M,VILLENEUVE D L,et al.Adverse outcome pathways-organizing toxicological information to improve decision making [J].J Pharmacol Exp Ther,2016,356(1):170-181. [8] OECD.Users’ handbook supplement to the guidance document for developing and assessing AOPs [R].France:Organisation for Economic Cooperation and Devleopment,Environment Directorate Paris,2014. [9] VILLENEUVE D L,CRUMP D,GARCIA-REYERO N,et al.Adverse outcome pathway development II:best practices [J].Toxicol Sci,2014,142(2):321-330. [10] LINKOV I,MASSEY O,KEISLER J,et al.From weight of evidence analysis to quantitative data integration tools:the path to improve both confidence and utility of hazard assessments [J].ALTEX,2015,32:5-10. [11] RHOMBERG L R,GOODMAN J E.A survey of frameworks for best practices in weight-ofevidence analyses [J].Crit Rev Toxicol,2013,43:753-784. [12] BECKER R A,ANKLEY G T,EDWARDS S W,et al.Increasing scientific confidence in adverse outcome pathways:application of tailored Bradford-Hill considerations for evaluating weight of evidence [J].Regul Toxicol Pharmacol,2015,72(3):514-537. [13] PERKINS E J,ANTCZAK P,BURGOON L,et al.Adverse outcome pathways for regulatory applications:examination of four case studies with different degrees of completeness and scientific confidence [J].Toxicol Sci,2015,148(1):14-25. [14] OECD.Organisation for economic co-operation and development.Guidance on grouping of chemicals:second edition.Environment directorate.(Series on Testing and Assessment No.194).Report No.:ENV/JM/MONO (2014)4,JT03356214 [R].Paris (FR):OECD,2014. [15] MEEK M E,BOOBIS A R,COTE I,et al.New developments in the evolution and application of the WHO/IPCS framework on mode of action/species concordance analysis [J].J Appl Toxicol,2014,34:1-18. [16] MEEK M E,PALERMO C M,BACHMAN A N,et al.Mode of action human relevance (MOA/HR) framework-evolution of the Bradford Hill considerations [J].Journal of Applied Toxicology,2014,34:595-606. [17] 陈彧,喻欢,程树军,等.基于有害结局通路原理的皮肤致敏测试替代方法进展[J].日用化学品科学,2016,39(4):4-9. [18] VILLENEUVE D,VOLZ D C,EMBRY MR,et al.Investigating alternatives to the fish early-life stage test:A strategy for discovering and annotating adverse outcome pathways for early fish development [J].Environ Toxicol Chem,2014,33(1):158-169. |